Who are the top shareholders of the Aristo Bio-Tech?

The top shareholder of Aristo Bio-Tech is Narendra Singh Barhat, holding 33.54%. Individual investors own 23.1%, with Kabra Sunil Murlimanohar as the highest public shareholder at 2.12%.

The top shareholders of Aristo Bio-Tech primarily include the promoters, with Narendra Singh Barhat holding the largest share at 33.54%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Kabra Sunil Murlimanohar, who holds 2.12%. Additionally, individual investors collectively own 23.1% of the company.

When is the next results date for Aristo Bio-Tech?

No Upcoming Board Meetings

Has Aristo Bio-Tech declared dividend?

Aristo Bio-Tech & Lifescience Ltd has declared a 4% dividend, amounting to 0.4 per share, with an ex-date of 13 Sep 2024. While the company has shown significant growth over the past year and two years, recent returns have been negative, indicating volatility.

Aristo Bio-Tech & Lifescience Ltd has declared a 4% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 4%<BR>- Amount per share: 0.4<BR>- Ex-date: 13 Sep 2024<BR><BR>Dividend Yield: 0.31%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.72%, the dividend return was 0%, resulting in a total return of -14.72%.<BR><BR>Over the past year, the price return was 52.65%, the dividend return was 0.49%, leading to a total return of 53.14%.<BR><BR>In the last 2 years, the price return was 102.87%, the dividend return was 1.01%, culminating in a total return of 103.88%.<BR><BR>For the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the last 4 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Over the past 5 years, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Overall, Aristo Bio-Tech has declared a dividend, and while the recent total returns show significant growth over the last year and two years, the returns in the shorter term have been negative, indicating volatility in the company's performance.

Who are the peers of the Aristo Bio-Tech?

Aristo Bio-Tech's peers include P I Industries, UPL, Bayer CropSci., and others, with varying management and growth risks. Dhanuka Agritech leads in 1-year returns at 32.70%, while Aristo Bio-Tech has a 0.00% return.

Peers: The peers of Aristo Bio-Tech are P I Industries, UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Aimco Pesticides, Super Crop Safe, Bhaskar Agrochem, Crop Life Scienc.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci. and Dhanuka Agritech, while Good management risk is found at P I Industries and Sumitomo Chemi. Average management risk is present at UPL, Aimco Pesticides, Bhaskar Agrochem, and Crop Life Scienc, whereas Below Average management risk is noted for Super Crop Safe. In terms of Growth, Excellent growth is seen at P I Industries, while Below Average growth is noted at UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Aimco Pesticides, Super Crop Safe, Bhaskar Agrochem, and Crop Life Scienc. Aristo Bio-Tech has Below Average growth as well. Capital Structure ratings show Excellent at P I Industries, Bayer CropSci., Sumitomo Chemi., and Dhanuka Agritech, while Average is seen at Aimco Pesticides, Crop Life Scienc, and Below Average at UPL, Super Crop Safe, and Bhaskar Agrochem.<BR><BR>Return Snapshot: Dhanuka Agritech has the highest 1-year return at 32.70%, while Aimco Pesticides has the lowest at -3.36%. Aristo Bio-Tech's 1-year return is 0.00%, which is lower than Dhanuka Agritech's and higher than Aimco Pesticides'. Additionally, Super Crop Safe and Natural Biocon have negative six-month returns.

What is the technical trend for Aristo Bio-Tech?

As of June 6, 2025, Aristo Bio-Tech's technical trend is mildly bullish, supported by a bullish MACD and moving averages, despite mixed signals from Dow Theory.

As of 6 June 2025, the technical trend for Aristo Bio-Tech has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the daily moving averages indicate a mildly bullish stance. Bollinger Bands also reflect a mildly bullish outlook on both weekly and monthly time frames. The KST is bullish on a weekly basis, and the OBV shows bullish momentum as well. However, Dow Theory presents a mixed picture with a mildly bullish weekly view contrasted by a bearish monthly perspective. Overall, the current technical stance is mildly bullish, driven by the strength of the MACD and moving averages, despite some mixed signals from Dow Theory.

Who are in the management team of Aristo Bio-Tech?

As of March 2022, the management team of Aristo Bio-Tech includes Narendra Singh Barhat (Chairman & Managing Director), Kusum Narendra Singh Barhat (Executive Director), Ketankumar Harkantbhai Joshi (Whole Time Director & CFO), and several directors, including independent directors and a company secretary. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Aristo Bio-Tech includes the following individuals:<BR><BR>1. Narendra Singh Barhat - Chairman & Managing Director<BR>2. Kusum Narendra Singh Barhat - Executive Director<BR>3. Ketankumar Harkantbhai Joshi - Whole Time Director & CFO<BR>4. Mr. Laxman Singh Rathore - Director<BR>5. Mr. Dipakkumar Harkant Joshi - Director<BR>6. Raghavende Matei - Independent Director<BR>7. Rashmi Ajaykumar Aahuja - Independent Director<BR>8. Neha Batra - Company Secretary & Compliance Officer<BR>9. Surendra Singh Lakhawat - Independent Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

What does Aristo Bio-Tech do?

Aristo Bio-Tech & Lifescience Ltd operates in the pesticides and agrochemicals sector as a micro-cap company, with a market cap of INR 87 Cr. It was incorporated in 2005 and became a public company in 2020, but recent revenue and profit data are unavailable.

Overview:<BR>Aristo Bio-Tech & Lifescience Ltd operates in the pesticides and agrochemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated on March 17, 2005, as "Aristo Bio-Tech and Lifescience Private Limited." It later converted into a public limited company, changing its name to "Aristo Bio-Tech and Lifescience Limited" on May 20, 2020. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 87 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 40<BR>Dividend Yield: 0.31%<BR>Debt-Equity: 0.60<BR>Return on Equity: 12.08%<BR>Price-to-Book: 2.60<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Aristo Bio-Tech?

As of 24th July, Aristo Bio-Tech & Lifescience Ltd has a market capitalization of 80.00 Cr, classified as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 33.61 Cr and Total Assets of 127.29 Cr.

As of 24th July, <BR><BR>Market Cap: Aristo Bio-Tech & Lifescience Ltd has a market capitalization of 80.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 33.61 Cr and Total Assets valued at 127.29 Cr.

Is Aristo Bio-Tech overvalued or undervalued?

As of September 23, 2025, Aristo Bio-Tech is considered very expensive and overvalued with a PE Ratio of 23.11, an EV to EBITDA of 12.36, and a PEG Ratio of 5.63, despite a strong one-year return of 35.1%, indicating that its current price of 137.80 is not justified compared to its peers.

As of 23 September 2025, the valuation grade for Aristo Bio-Tech has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is considered overvalued based on its current metrics. Key ratios include a PE Ratio of 23.11, an EV to EBITDA of 12.36, and a PEG Ratio of 5.63, all of which suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to peers, Aristo Bio-Tech's PE Ratio is notably lower than UPL's 38.05 and P I Industries' 34.2, both of which are categorized as attractive or very expensive, respectively. Additionally, while the company has shown a strong one-year return of 35.1%, outperforming the Sensex's decline of 2.97%, the overall valuation metrics suggest that it is not justified at its current price level of 137.80.

How has been the historical performance of Aristo Bio-Tech?

Aristo Bio-Tech has demonstrated consistent growth in net sales and profitability over the past five years, with net sales increasing from INR 165.76 crore in March 2022 to INR 318.09 crore in March 2025, despite rising raw material costs impacting profit margins. The company has also improved its operating profit and cash flow, indicating a strengthening financial position.

Answer:<BR>The historical performance of Aristo Bio-Tech shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Aristo Bio-Tech's net sales have increased significantly from INR 165.76 crore in March 2022 to INR 318.09 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 167.22 crore in March 2021 to INR 318.09 crore in March 2025. However, raw material costs have also escalated, reaching INR 295.60 crore in March 2025, which has impacted the operating profit margin, which decreased from 4.0% in March 2023 to 2.91% in March 2025. Despite this, the operating profit (PBDIT) has shown improvement, growing from INR 4.36 crore in March 2021 to INR 9.72 crore in March 2025. Profit before tax has also increased, reaching INR 5.47 crore in March 2025, while profit after tax rose to INR 4.06 crore in the same period. The company's total assets have expanded from INR 77.00 crore in March 2022 to INR 140.62 crore in March 2025, indicating robust growth in its financial position. Total liabilities have also increased, but the shareholder's funds have grown significantly, reflecting a strengthening equity base. Cash flow from operating activities improved to INR 10.00 crore in March 2025, compared to INR -2.00 crore in March 2023, demonstrating better cash generation capabilities. Overall, Aristo Bio-Tech has shown a positive trend in sales and profitability, despite rising costs and liabilities.

Which are the latest news on Aristo Bio-Tech?

Why is Aristo Bio-Tech falling/rising?

As of 04-Dec, Aristo Bio-Tech & Lifescience Ltd's stock price is 116.95, down 0.51%, with a year-to-date decline of 12.07%. Despite a recent weekly gain, the stock underperforms against its sector and shows signs of a longer-term downward trend, although investor participation has increased significantly.

As of 04-Dec, Aristo Bio-Tech & Lifescience Ltd's stock price is currently at 116.95, reflecting a decrease of 0.6, or 0.51%. The stock has shown a negative performance over various time frames, including a year-to-date decline of 12.07% compared to a 10.10% increase in the benchmark Sensex. Over the past month, the stock has fallen by 9.34%, while the Sensex has risen by 1.70%. <BR><BR>Despite a recent weekly gain of 4.37%, the stock has underperformed against its sector today by 1.34%. Additionally, while the stock is currently above its 5-day moving average, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a potential downward trend in the longer term. <BR><BR>On a positive note, there has been a significant increase in investor participation, with delivery volume rising by 85.19% compared to the 5-day average. However, the overall liquidity remains low, as it is based on only 2% of the 5-day average traded value. This combination of factors suggests that while there may be some short-term interest, the stock is facing broader challenges that contribute to its current decline.